News & Analysis on Clinical Trial Services & Contract Research And Development
GlaxoSmithKline (GSK) and Fabre-Kramer Pharmaceuticals (FKP) were dealt a blow last week as their potential first in class, once-daily antidepressant treatment received another thumbs down from US regulators.
Japan will only be receiving 50 per cent of its usual supply of the blockbuster flu drug Tamiflu (oseltamivir) this year, thanks to significantly reduced demand following reports of suicidal behaviour in adolescents taking the medication.
Inherited genetic disorders could be treated with a new stem cell-based drug delivery therapy through the use of microcapsules.
BioInvent and ThromboGenics' new anticancer antibody is poised to enter clinical trials and could prove a serious rival to VEGF-blocking drugs, due to fewer side-effects and less drug resistance.